Dateline City:
KENILWORTH, N.J.
Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
granted Breakthrough Therapy Designation to KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, for the treatment of
patients with microsatellite instability high (MSI-H) metastatic
colorectal cancer. This is the third Breakthrough Therapy Designation
granted for KEYTRUDA.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more